Відео

Truly insightful. A must-watch every year end!

Always valuable, thanks to you and the Atlas team!

Very impressive, love to see the birds-eye view of cutting edge biotech research.

Excellent update, as usual!

Excellent review. Thank you Bruce for the clarity and the data driven analysis.

great as usual - why so many ads this year . . . ??

Atlas fails on diversity - all white male partners and no ethnic diversity in junior roles.

Thanks for pulling these excellent presentations together each year. Much appreciated.

you should mention side effects of GLP inhibitors though

So basically being cheap is only way to make money. Selling diet pills? Reminds me of Wall-E.

Than you very much!

A comprehensive review of the bio innovation landscape! Thank you

it looks like the government destroys the market again

Thank you, Bruce!

Nice job as always Bruce! Rock on

Outstanding succinct review. Thank you for sharing.

Bruce evey year I wait for your review. This is the best review of our industry. God bless you

Any slides pdf?

Year after year, Bruce and team create and share what consistently feels like the best biopharma review in the business - always so great to see this consolidated perspective.

Highly enjoyed the overview. Thank you! I'd like connect with you sometime.

This is a great overview of the year in biotech venture generally, and Atlas specifically.

Nice overview Bruce! As always very insightful. I wouldn't celebrate the amyloid targeting drugs, it's going to harm the entire AD pipeline -- by doubling down on amyloid at the expense of fresh new approaches.

great presentation Bruce

Fanning the flames of convid

Very compelling as usual. Keep up the great analysis, Bruce and team!

Bruce. Always doing a great recap and state of the (union) of the biotech community. Kudos.

Another great presentation Bruce. I also lament the underwhelming rate of progress, especially in age-related diseases like cancer (3% gain in 5-year survival after 20 years of research and hundreds of billions spent -- hopefully 'new' paradigms I/O will steepen the slope). Most biopharma resources go into oncology and yet we can barely move the needle for solid tumors -- maybe we need fresh ideas. The major risk factor for cancer, CVD, and dementia is biological age. So what if we could target the molecular damage that causes aging, and thereby all of these diseases? We can already extend healthy lifespan in mice by up to 30% with no negative side effects -- for example, by senescent cell ablation, autophagy enhancement, and various types of gene and cell therapy that address the primary, causal 'Hallmarks of Aging.' This 'geroscience' approach is led by groups like Apollo Ventures and Cambrian Biopharma (in stealth mode, stay tuned) -- target the biology of aging and develop a 'pipeline-in-a-pill' for multiple age-related diseases and, one day, as a prophylactic against aging itself. Keep up the great work. "From discoveries in ageing research to therapeutics for healthy ageing" www.nature.com/articles/s41586-019-1365-2 "The Hallmarks of Aging" www.cell.com/fulltext/S0092-8674(13)00645-4

Great overview, many thanks Bruce

Very nice design